Clinical Trial Update: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial registration outlines a Phase 1/2 pediatric study of a multi-drug regimen (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• CYTARABINE (CYTARABINE)
• DASATINIB (Dasatinib)
• DEXAMETHASONE (Dexamethasone)
• Venetoclax (venetoclax)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1, Phase 2 | Status: RECRUITING